New Delhi: Russian Direct Investment Fund (RDIF) and Virchow Biotech, based in Hyderabad, on Monday announced an agreement to produce up to 200 million doses of Sputnik V vaccine in India.
The transfer of technology is expected to be completed in the second quarter of 2021, followed by the full-scale commercial production of Sputnik V, RDIF and Virchow Biotech in a joint statement.
Virchow Biotech capabilities will help facilitate the global supply of Sputnik V to international partners of RDIF.
“The agreement with Virchow Biotech is an important step in facilitating the full – scale local production of the vaccine in India and in providing our international partners worldwide,” said Kirill Dmitriev, CEO of RDIF.
According to the statement, the efficiency of Sputnik V is 91.6 percent, as confirmed by the data published in the Lancet.
‘We are pleased to sign a co-operation agreement with RDIF to manufacture the Sputnik V coronavirus vaccine. “Virchow’s proven capabilities in large – scale medicine manufacturing should help meet the global demand for this vaccine,” said Tummuru Murali, Managing Director of Virchow Biotech.
On March 19, RDIF and Stelis Biopharma of India said they had worked together to produce and deliver a minimum of 200 million doses of Sputnik V. COVID-19 vaccine.
Source: Telangana Today